^
BIOMARKER:

NPM1 mutation

i
Other names: Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin), Testicular Tissue Protein Li 128, Nucleolar Protein NO38, Numatrin, NPM1, Nucleophosmin 1, Nucleophosmin/Nucleoplasmin Family, Member 1, Nucleolar Phosphoprotein B23
Entrez ID:
Related biomarkers:
Phase 3
Kronos Bio
Recruiting
Last update posted :
05/18/2022
Initiation :
11/30/2021
Primary completion :
12/30/2023
Completion :
12/30/2026
FLT3 • NPM1
|
FLT3 mutation • NPM1 mutation
|
cytarabine • entospletinib (GS-9973)
Phase 2
Washington University School of Medicine
Recruiting
Last update posted :
05/11/2022
Initiation :
07/06/2016
Primary completion :
07/31/2024
Completion :
07/31/2024
FLT3 • NPM1 • CEBPA
|
FLT3-ITD mutation • NPM1 mutation • CEBPA mutation
|
cytarabine • Rydapt (midostaurin)
Phase 2
Institute of Hematology & Blood Diseases Hospital
Recruiting
Last update posted :
05/04/2022
Initiation :
05/01/2022
Primary completion :
02/28/2023
Completion :
08/31/2023
NPM1 • RUNX1 • RUNX1T1 • NUP214 • DEK
|
NPM1 mutation
|
Venclexta (venetoclax) • azacitidine • daunorubicin
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
04/20/2022
Initiation :
02/27/2019
Primary completion :
01/01/2024
Completion :
01/01/2024
ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA
|
NPM1 mutation • CEBPA mutation • PDGFRA rearrangement
|
Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
04/14/2022
Initiation :
03/30/2018
Primary completion :
01/10/2025
Completion :
11/10/2025
NPM1 • IKZF1 • KMT2A • CEBPA
|
NPM1 mutation • MLL rearrangement • CEBPA mutation • MLL rearrangement
|
cyclophosphamide • mycophenolate mofetil
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
04/13/2022
Initiation :
03/25/2021
Primary completion :
11/01/2022
Completion :
11/01/2022
FLT3 • NPM1
|
NPM1 mutation
|
Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • azacitidine • methotrexate • vincristine • leucovorin calcium • mesna • Riabni (rituximab-arrx) • DS-1594 • Decadron (dexamethasone) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • Noxafil (posaconazole) • TQB2303 (rituximab biosimilar) • TevaGrastim (filgrastim biosimilar) • prednisone delayed-release tablet • voriconazole
Phase 2
University of Rochester
Recruiting
Last update posted :
04/11/2022
Initiation :
02/28/2019
Primary completion :
04/01/2023
Completion :
04/01/2023
FLT3 • ABL1 • BCR • NPM1 • CD19 • CD22 • CD79A
|
FLT3-ITD mutation • NPM1 mutation
Phase 1/2
Sumitomo Pharma Oncology, Inc.
Recruiting
Last update posted :
04/06/2022
Initiation :
02/28/2022
Primary completion :
01/02/2025
Completion :
02/01/2025
NPM1
|
NPM1 mutation
|
DSP-5336 • Noxafil (posaconazole) • fluconazole oral
Phase 2
Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting
Last update posted :
03/16/2022
Initiation :
03/01/2022
Primary completion :
01/01/2025
Completion :
01/01/2025
FLT3 • ABL1 • NPM1
|
NPM1 mutation
|
Venclexta (venetoclax) • azacitidine
Phase 2
Technische Universität Dresden
Recruiting
Last update posted :
03/14/2022
Initiation :
08/21/2019
Primary completion :
08/01/2023
Completion :
08/01/2024
NPM1
|
NPM1 mutation
|
Keytruda (pembrolizumab) • azacitidine
Phase 2
University of Leipzig
Active, not recruiting
Last update posted :
01/24/2022
Initiation :
01/01/2021
Primary completion :
11/01/2023
Completion :
11/01/2024
KIT • NPM1 • CD34
|
NPM1 mutation
|
azacitidine • pevonedistat (MLN4924)
Phase 2
Stichting Hemato-Oncologie voor Volwassenen Ned...
Withdrawn
Last update posted :
12/22/2021
Initiation :
01/01/2022
Primary completion :
08/01/2024
Completion :
12/01/2026
NPM1
|
NPM1 mutation
|
flotetuzumab (MGD006)
Phase 3
Medical College of Wisconsin
Completed
Last update posted :
12/01/2021
Initiation :
06/01/2012
Primary completion :
09/11/2020
Completion :
09/11/2020
NPM1 • CEBPA • HLA-DRB1 • HLA-B • HLA-C
|
NPM1 mutation • MLL rearrangement • CEBPA mutation • MLL rearrangement
|
cyclophosphamide • fludarabine IV • mycophenolate mofetil • tacrolimus intravenous • tacrolimus oral
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
11/05/2021
Initiation :
05/15/2017
Primary completion :
05/01/2028
Completion :
12/01/2029
NPM1 • IKZF1 • KMT2A • CEBPA
|
NPM1 mutation • MLL rearrangement • CEBPA mutation • MLL rearrangement
|
cyclophosphamide • sirolimus • fludarabine IV • mycophenolate mofetil
Phase 1/2
Assistance Publique - Hôpitaux de Paris
Recruiting
Last update posted :
10/29/2021
Initiation :
10/01/2021
Primary completion :
09/01/2023
Completion :
05/01/2025
FLT3 • NPM1 • CD8 • CD34 • HLA-DRB1 • CD4 • CD27 • CD7
|
FLT3-ITD mutation • NPM1 mutation
Phase 3
University of Ulm
Completed
Last update posted :
09/29/2021
Initiation :
05/12/2010
Primary completion :
09/01/2021
Completion :
09/01/2021
NPM1
|
NPM1 mutation
|
Mylotarg (gemtuzumab ozogamicin)
Phase 2
DCPrime BV
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
10/15/2018
Primary completion :
03/01/2022
Completion :
12/01/2022
NPM1
|
NPM1 mutation
|
DCP-001
Phase N/A
PETHEMA Foundation
Recruiting
Last update posted :
09/06/2021
Initiation :
10/01/2019
Primary completion :
10/01/2022
Completion :
10/01/2022
TP53 • FLT3 • NPM1 • IDH2 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • SMC1A
|
NPM1 mutation • CEBPA mutation • U2AF1 mutation
Phase 2
Rutgers, The State University of New Jersey
Completed
Last update posted :
08/24/2021
Initiation :
01/01/2009
Primary completion :
04/26/2016
Completion :
04/26/2016
FLT3 • NPM1
|
NPM1 mutation
|
cytarabine • idarubicin hydrochloride
Phase 2
Masonic Cancer Center, University of Minnesota
Active, not recruiting
Last update posted :
08/16/2021
Initiation :
01/02/2019
Primary completion :
07/01/2023
Completion :
08/01/2023
FLT3 • NPM1 • KMT2A • CEBPA • HLA-DRB1
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • CEBPA mutation • MLL rearrangement • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • mycophenolate mofetil • spanlecortemlocel (MGTA-456) • tacrolimus intravenous
Phase 1/2
Syndax Pharmaceuticals
Recruiting
Last update posted :
05/06/2021
Initiation :
11/05/2019
Primary completion :
07/01/2022
Completion :
01/01/2024
KMT2A
|
NPM1 mutation • MLL rearrangement • MLL rearrangement
|
revumenib (SNDX-5613) • Tybost (cobicistat)
Phase 2
University of California, Irvine
Recruiting
Last update posted :
04/13/2021
Initiation :
02/19/2020
Primary completion :
09/30/2021
Completion :
09/30/2022
NPM1 • CEBPA
|
NPM1 mutation
|
Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)
Phase 2
The University of Hong Kong
Recruiting
Last update posted :
12/31/2020
Initiation :
01/01/2021
Primary completion :
12/31/2023
Completion :
12/31/2024
NPM1
|
NPM1 mutation
|
azacitidine • arsenic trioxide
Phase 2/3
University Hospital, Angers
Recruiting
Last update posted :
10/20/2020
Initiation :
01/01/2015
Primary completion :
06/01/2024
FLT3 • NPM1
|
FLT3-ITD mutation • NPM1 mutation
|
Venclexta (venetoclax) • cytarabine • daunorubicin • idarubicin hydrochloride • dexamethasone • Qinprezo (vosaroxin) • cyclosporine • mycophenolate mofetil
Phase 1/2
Versailles Hospital
Active, not recruiting
Last update posted :
08/10/2020
Initiation :
07/01/2013
Primary completion :
11/01/2020
Completion :
11/01/2023
FLT3 • NPM1 • WT1
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • NPM1 expression • FLT3 wild-type
|
Iclusig (ponatinib) • cytarabine
Phase N/A
ECOG-ACRIN Cancer Research Group
Completed
Last update posted :
07/31/2020
Initiation :
03/23/2006
Primary completion :
10/15/2009
Completion :
10/15/2009
NPM1
|
NPM1 mutation
Phase 1/2
Institute of Hematology & Blood Diseases Hospital
Recruiting
Last update posted :
03/20/2020
Initiation :
02/08/2017
Primary completion :
12/01/2021
Completion :
12/01/2022
NPM1
|
NPM1 mutation
|
cytarabine • Vesanoid (tretinoin) • arsenic trioxide
Phase 2
Celgene
Completed
Last update posted :
12/20/2019
Initiation :
08/12/2015
Primary completion :
10/10/2018
Completion :
10/08/2019
FLT3 • NPM1 • RUNX1 • KMT2A • RUNX1T1
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement
|
azacitidine
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
08/22/2019
Initiation :
01/29/2011
Primary completion :
06/28/2018
Completion :
06/28/2018
FLT3 • NPM1 • CEBPA • CD4
|
FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)
|
peripheral blood stem cell transplantation
Phase 1
Orsenix LLC
Completed
Last update posted :
03/25/2019
Initiation :
12/02/2016
Primary completion :
02/28/2019
Completion :
02/28/2019
NPM1
|
NPM1 mutation
|
arsenic trioxide • arsenic trioxide oral (SY-2101)
Phase 2
Sellas Life Sciences Group
Completed
Last update posted :
11/30/2018
Initiation :
12/01/2010
Primary completion :
02/01/2018
Completion :
02/01/2018
FLT3 • NPM1 • WT1
|
NPM1 mutation
|
Zeltherva (galinpepimut-S)
Phase 1/2
Ludwig-Maximilians - University of Munich
Completed
Last update posted :
10/12/2018
Initiation :
11/05/2013
Primary completion :
03/31/2018
Completion :
09/30/2018
NPM1
|
NPM1 mutation
Phase 3
University of Ulm
Completed
Last update posted :
08/01/2018
Initiation :
03/01/2011
Primary completion :
07/13/2018
Completion :
07/13/2018
NPM1
|
NPM1 mutation
|
cytarabine • etoposide IV
Phase 2
Stanford University
Withdrawn
Last update posted :
05/21/2018
Initiation :
05/01/2013
Primary completion :
05/01/2015
NPM1
|
NPM1 mutation
|
arsenic trioxide
Phase 2
Masonic Cancer Center, University of Minnesota
Withdrawn
Last update posted :
12/01/2017
Initiation :
06/01/2016
Primary completion :
09/01/2018
Completion :
09/01/2018
NPM1 • KMT2A • CEBPA • HLA-DRB1 • HLA-B
|
NPM1 mutation • MLL rearrangement • CEBPA mutation • MLL rearrangement
|
cyclophosphamide • fludarabine IV
Phase 1/2
Coronado Biosciences, Inc.
Active, not recruiting
Last update posted :
06/29/2017
Initiation :
12/01/2012
Primary completion :
03/01/2016
Completion :
02/01/2018
FLT3 • NPM1 • HLA-B
|
FLT3 mutation • NPM1 mutation • Chr del(5q)
|
CNDO-109
Phase N/A
Southwest Oncology Group
Completed
Last update posted :
03/06/2015
Initiation :
04/01/2012
Primary completion :
05/01/2012
Completion :
05/01/2012
FLT3 • NPM1 • CEBPA • CD33
|
FLT3-ITD mutation • NPM1 mutation